Novo Holdings A/S’s Acceleron Pharma XLRN Stock Holding History

Novo Holdings A/S’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-119,708	Closed	-$4.73M	–	32
2019 Q3	$4.73M	Hold	119,708	–	–	0.81%	22
2019 Q2	$4.92M	Sell	119,708 -78,553	-40%	-$3.25M	0.69%	23
2019 Q1	$9.23M	Sell	198,261 -222,032	-53%	-$9.75M	1.37%	15
2018 Q4	$18.3M	Sell	420,293 -229,707	-35%	-$11.5M	2.58%	6
2018 Q3	$37.2M	Sell	650,000 -453,937	-41%	-$22.3M	2.95%	4
2018 Q2	$53.6M	Sell	1,103,937 -450,000	-29%	-$16.4M	5.39%	2
2018 Q1	$60.8M	Hold	1,553,937	–	–	7.62%	2
2017 Q4	$65.9M	Hold	1,553,937	–	–	9.24%	2
2017 Q3	$58M	Hold	1,553,937	–	–	7.55%	2
2017 Q2	$47.2M	Hold	1,553,937	–	–	5.65%	3
2017 Q1	$41.1M	Buy	1,553,937 +313,764	+25%	+$8.27M	4.38%	7
2016 Q4	$31.6M	Buy	1,240,173 +336,340	+37%	+$10.7M	3.01%	8
2016 Q3	$32.7M	Buy	903,833 +217,970	+32%	+$7.22M	2.91%	8
2016 Q2	$23.3M	Buy	685,863 +12,800	+2%	+$416K	2.45%	9
2016 Q1	$17.8M	Buy	+673,063	New	+$19.6M	1.95%	8

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Novo Holdings A/S's XLRN Position: Q4 2019 in Review

Novo Holdings A/S sold out of Acceleron Pharma (XLRN) in Q4 2019, closing a stake of 119,708 shares — an estimated $4.73M sold.

Novo Holdings A/S first reported a position in XLRN in Q1 2016 and held it in 15 quarters. The position peaked at $65.9M in Q4 2017. 183 funds tracked by Wall St. Rank hold XLRN as of Q4 2019.

Novo Holdings A/S reported no remaining Acceleron Pharma position as of Q4 2019 after selling out during the quarter.
Novo Holdings A/S sold 119,708 Acceleron Pharma shares in Q4 2019, an estimated $4.73M.
Novo Holdings A/S first reported a position in Acceleron Pharma in Q1 2016 and held it in 15 quarters.
Novo Holdings A/S's Acceleron Pharma position peaked at $65.9M in Q4 2017.
183 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2019.

Based on Novo Holdings A/S's 13F filing for Q4 2019, filed 14 Feb 2020.